8-KMaterial AgreementsOther EventsExhibits & Filings

THERMO FISHER SCIENTIFIC INC. 8-K Report, Material Agreement (Oct 22, 2021)

Filed October 22, 2021For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO) filed an 8-K on October 21, 2021, to report the issuance of a significant debt offering. The company successfully raised approximately $5.82 billion in net proceeds from the sale of various senior notes, including both floating rate and fixed rate tranches with maturities ranging from 18 months to 4 years. This capital infusion is primarily intended to fund a portion of the cash consideration for the previously announced acquisition of PPD, Inc. The company also retains flexibility to use proceeds for general corporate purposes, such as acquisitions, debt repayment, working capital, or share repurchases. This substantial debt issuance highlights Thermo Fisher's active capital management strategy, aimed at financing strategic growth initiatives. Investors should note the specific terms of the notes, including interest payment schedules and redemption provisions. Importantly, the issuance is directly linked to the PPD acquisition, with certain notes subject to mandatory redemption if the acquisition does not close by October 15, 2022, or if the merger agreement is terminated. Additionally, covenants within the indenture are standard for unsecured debt, with provisions for change of control and default events.

Key Highlights

  • 1Thermo Fisher Scientific raised approximately $5.82 billion in net proceeds from a public offering of senior notes.
  • 2The offering included both floating rate notes and fixed rate notes with maturities ranging from 18 months to 4 years.
  • 3Net proceeds are primarily designated to finance a portion of the cash consideration for the PPD, Inc. acquisition.
  • 4A portion of the proceeds may also be used for general corporate purposes, including acquisitions, debt repayment, working capital, and share repurchases.
  • 5Specific notes (2023 Floating Rate, 2024 Floating Rate, 2023 Fixed Rate, 2024 Fixed Rate) are subject to special mandatory redemption at 101% of principal if the PPD Acquisition does not close by October 15, 2022, or the agreement is terminated.
  • 6The Notes are general unsecured obligations of the Company, ranking equally with existing unsecured and unsubordinated indebtedness.
  • 7The Indenture includes standard covenants restricting the incurrence of debt secured by liens on Principal Properties and sale-leaseback transactions, as well as limitations on mergers, consolidations, and asset sales.

Frequently Asked Questions

Thermo Fisher Scientific issued approximately $5.82 billion in net proceeds from the sale of various senior notes. The primary intended use of these proceeds is to finance a portion of the cash consideration for the acquisition of PPD, Inc. The company may also use a portion for general corporate purposes such as acquisitions, debt repayment, working capital, and capital expenditures, or temporarily invest the proceeds.

The company issued several tranches of senior notes: 18-Month Floating Rate Senior Notes due 2023, Floating Rate Senior Notes due 2023, Floating Rate Senior Notes due 2024, 0.797% Senior Notes due 2023, and 1.215% Senior Notes due 2024. Maturities range from April 18, 2023, for the 18-Month Floating Rate Notes, to October 18, 2024, for the 2024 Floating Rate Notes and 2024 Fixed Rate Notes.

If Thermo Fisher Scientific does not consummate the PPD Acquisition on or prior to October 15, 2022, or if the merger agreement related to the acquisition is terminated prior to that date, the company will be required to redeem all of the 2023 Floating Rate Notes, 2024 Floating Rate Notes, 2023 Notes, and 2024 Notes (collectively, the "SMR Notes") at a redemption price of 101% of their aggregate principal amount, plus accrued interest.

The notes are general unsecured obligations of the Company. They rank equally with the Company's existing and any future unsecured and unsubordinated indebtedness. They are effectively subordinated to any secured indebtedness of the Company to the extent of the collateral securing such debt, and structurally subordinated to all indebtedness and liabilities of its subsidiaries.